Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature.

Am J Ther

1Internal Medicine Department, University of Toledo Medical Center, Toledo, OH 2Division of Gastroenterology, UP Digestive Health, War Memorial Hospital, Marie, MI.

Published: September 2014

Golimumab is a human IgG monoclonal antibody specific for human tumor necrosis factor alpha. Golimumab has been approved for use in rheumatological conditions; however, its use in inflammatory bowel disease is still being evaluated in clinical trials. We report a case of an exacerbation of ulcerative proctitis after starting on golimumab for ankylosing spondylitis.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e31825e6089DOI Listing

Publication Analysis

Top Keywords

inflammatory bowel
8
bowel disease
8
ankylosing spondylitis
8
golimumab
4
golimumab induce
4
induce exacerbation
4
exacerbation inflammatory
4
disease treatment
4
treatment ankylosing
4
spondylitis case
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!